Sol Gel Technologies (NASDAQ:SLGL)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Wednesday. They presently have a $21.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 229.52% from the stock’s previous close.
The analysts wrote, “We have valued Sol-Gel based on a discounted cash flow (DCF) analysis. This yields a value of $102M for TWIN, assuming a 50% probability of success, and a $323M valuation for Epsolay, assuming a 60% probability of success.””
SLGL has been the topic of a number of other reports. ValuEngine upgraded Sol Gel Technologies from a “hold” rating to a “buy” rating in a report on Monday, August 20th. Zacks Investment Research upgraded Sol Gel Technologies from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a report on Tuesday, November 20th. Six equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and a consensus target price of $16.75.
Shares of NASDAQ SLGL traded down $0.27 during mid-day trading on Wednesday, reaching $6.37. The company had a trading volume of 13,673 shares, compared to its average volume of 12,450. The stock has a market capitalization of $125.65 million and a price-to-earnings ratio of -1.27. Sol Gel Technologies has a 1-year low of $5.98 and a 1-year high of $16.48.
Sol Gel Technologies (NASDAQ:SLGL) last issued its earnings results on Tuesday, November 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.16. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.05 million. As a group, sell-side analysts expect that Sol Gel Technologies will post -1.81 EPS for the current year.
Hedge funds have recently modified their holdings of the company. Raymond James & Associates purchased a new position in shares of Sol Gel Technologies during the second quarter valued at $102,000. Alpine Global Management LLC purchased a new position in shares of Sol Gel Technologies during the second quarter valued at $118,000. Finally, Delek Group Ltd. grew its holdings in shares of Sol Gel Technologies by 22.3% during the second quarter. Delek Group Ltd. now owns 1,269,816 shares of the company’s stock valued at $9,803,000 after buying an additional 231,786 shares in the last quarter. Institutional investors and hedge funds own 20.37% of the company’s stock.
Sol Gel Technologies Company Profile
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris; and VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea.
See Also: What is a Futures Contract?
Receive News & Ratings for Sol Gel Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sol Gel Technologies and related companies with MarketBeat.com's FREE daily email newsletter.